Contact PR

To use this feature, join Babbler easily !

arrow_back

Babbler allows PR people and reporters to collaborate a better way.

By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.

Their newsrooms are already on Babbler

You're 1 click away from signing up

Previous

Nice to see you again !

Press release

Our focus on improving outcomes for people with diabetes, now and for the future
timer minutes reading time minute reading time

Copy link
Sanofi at EASD | 54th ANNUAL MEETING | Berlin | October 1-5
our-focus-on-improving-outcomes-for-people-with-diabetes-now-and-for-the-future

Click to get original image size

The latest findings from BRIGHT, the first head-to-head randomized controlled trial comparing Toujeo® (insulin glargine 300 Units/mL) with insulin degludec, lead the wealth of medical data Sanofi is contributing to the scientific program at this year’s EASD congress in Berlin.

  • More than 47 Sanofi-related contributions at EASD 2018
  • 14 abstracts relating to Toujeo

  • Health & Medicine
  • Medicine
inscrit avec succès

Congratulations, you're registered on Babbler!

Discover now all the news waiting for you on Babbler: visit your newsfeed.!

Your topics have been selected, you can change it by clicking here

  • Health & Medicine
  • Medicine